A feasibility study evaluating surgery for mesothelioma after radiation therapy: The "SMART" approach for resectable malignant pleural mesothelioma

Journal of Thoracic Oncology

Volumn 9, Issue 3, 2014, Pages 397-402

  Cho, B C John ^a   Feld, Ron ^a   Leighl, Natasha ^a   Opitz, Isabelle ^a   Anraku, Masaki ^a   Tsao, Ming Sound ^a   Hwang, David M ^a   Hope, Andrew ^a   De Perrot, Marc ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Accelerated radiation; Extrapleural pneumonectomy; Hemithoracic radiotherapy; High dose radiation; Mesothelioma; Multimodality therapy; Neoadjuvant therapy

Indexed keywords

CISPLATIN; PEMETREXED;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHYLOTHORAX; DISEASE FREE SURVIVAL; EMPYEMA; FEASIBILITY STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HEMATOTHORAX; HUMAN; INTENSITY MODULATED RADIATION THERAPY; KIDNEY DYSFUNCTION; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA EMPYEMA; PLEURA MESOTHELIOMA; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RADIATION DOSE; THROMBOEMBOLISM; WOUND DEHISCENCE; WOUND INFECTION;

ADULT; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; PNEUMONECTOMY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY, INTENSITY-MODULATED; SURVIVAL RATE;

EID: 84894545672     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000078     Document Type: Article

References (29)

1. Stayner L, Welch LS, Lemen R. The worldwide pandemic of asbestos-related diseases. Annu Rev Public Health 2013;34:205-216.
2. Connelly RR, Spirtas R, Myers MH, et al. Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst 1987;78:1053-1060.
3. Bianchi C, Giarelli L, Grandi G, et al. Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev 1997;6:162-166.
4. Peto J, Hodgson JT, Matthews FE, et al. Continuing increase in mesothelioma mortality in Britain. Lancet 1995;345:535-539.
5. Law MR, Hodson ME, Turner-Warwick M. Malignant mesothelioma of the pleura: Clinical aspects and symptomatic treatment. Eur J Respir Dis 1984;65:162-168.
6. Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 332 patients. J Clin Oncol 1989;7:1157-1168.
7. Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998;16:145-152.
8. Treasure T, Lang-Lazdunski L, Waller D, et al MARS Trialists. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: Clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011;12:763-772.
9. Weder W, Stahel RA, Baas P, et al. The MARS feasibility trial: Conclusions not supported by data. Lancet Oncol 2011;12:1093-1094.
10. Rusch V, Baldini EH, Bueno R, et al. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: Meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass. J Thorac Cardiovasc Surg 2013;145:909-1110.
11. de Perrot M, Feld R, Cho BC, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:1413-1418.
12. de Perrot M, Uy K, Anraku M, et al. Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2007;133:111-116.
13. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122:788-795.
14. Gomez DR, Hong DS, Allen PK, et al. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol 2013;8:238-245.
15. de Perrot M. Use of the posterior pericardium to cover the bronchial stump after right extrapleural pneumonectomy. Ann Thorac Surg 2013;96:706-708.
16. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press, 2004.
17. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 1996;14:1-12.
18. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-181.
19. de Perrot M, McRae K, Anraku M, et al. Risk factors for major complications after extrapleural pneumonectomy for malignant pleural mesothelioma. Ann Thorac Surg 2008;85:1206-1210.
20. Yan TD, Boyer M, Tin MM, et al. Extrapleural pneumonectomy for malignant pleural mesothelioma: Outcomes of treatment and prognostic factors. J Thorac Cardiovasc Surg 2009;138:619-624.
21. Rusch VW, Giroux D, Kennedy C, et al IASLC Staging Committee. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol 2012;7:1631-1639.
22. Flores RM, Routledge T, Seshan VE, et al. The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: Implications for revision of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg 2008;136:605-610.
23. Rice DC, Steliga MA, Stewart J, et al. Endoscopic ultrasound-guided fine needle aspiration for staging of malignant pleural mesothelioma. Ann Thorac Surg 2009;88:862-868.
24. Stewart DJ, Martin-Ucar AE, Edwards JG, et al. Extra-pleural pneumonectomy for malignant pleural mesothelioma: The risks of induction chemotherapy, right-sided procedures and prolonged operations. Eur J Cardiothorac Surg 2005;27:373-378.
25. Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004;128:138-146.
26. Opitz I, Kestenholz P, Lardinois D, et al. Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Eur J Cardiothorac Surg 2006;29:579-584.
27. Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: Changing strategies for cancer treatment. Blood 2009;114:589-595.
28. Levy A, Chargari C, Cheminant M, et al. Radiation therapy and immunotherapy: Implications for a combined cancer treatment. Crit Rev Oncol Hematol 2013;85:278-287.
29. Ludgate CM. Optimizing cancer treatments to induce an acute immune response: Radiation Abscopal effects, PAMPs, and DAMPs. Clin Cancer Res 2012;18:4522-4525.